Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR C797S/L858R (#RDB15495)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S and L858R, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15495 pENTER-EGFR C797S/L858R DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR C797S/L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15495).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15495_A7K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter, attL1, insert 5'
Sequence file: RDB15495_A7K8a.seq check
>D04925A8_A7K8_2_rrnBT1ter_F2_H04_22_ABI24.ab1
    1 AGCCAGATCT TCCGACTGAG CCTTTCGTTT TATTTGATGC CTGGCAGTTC CCTACTCTCG
   61 CGTTAACGCT AGCATGGATG TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGTCTTA
  121 AGCTCGGGCC CCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA
  181 TTGATGAGCA ATGCTTTTTT ATAATGCCAA CTTTGTACAA AAAAGCAGGC TCCGCGGCCG
  241 CCCCCTTCAC CATGCGACCC TCCGGGACGG CCGGGGCAGC GCTCCTGGCG CTGCTGGCTG
  301 CGCTCTGCCC GGCGAGTCGG GCTCTGGAGG AAAAGAAAGT TTGCCAAGGC ACGAGTAACA
  361 AGCTCACGCA GTTGGGCACT TTTGAAGATC ATTTTCTCAG CCTCCAGAGG ATGTTCAATA
  421 ACTGTGAGGT GGTCCTTGGG AATTTGGAAA TTACCTATGT GCAGAGGAAT TATGATCTTT
  481 CCTTCTTAAA GACCATCCAG GAGGTGGCTG GTTATGTCCT CATTGCCCTC AACACAGTGG
  541 AGCGAATTCC TTTGGAAAAC CTGCAGATCA TCAGAGGAAA TATGTACTAC GAAAATTCCT
  601 ATGCCTTAGC AGTCTTATCT AACTATGATG CAAATAAAAC CGGACTGAAG GAGCTGCCCA
  661 TGAGAAATTT ACAGGAAATC CTGCATGGCG CCGTGCGGTT CAGCAACAAC CCTGCCCTGT
  721 GCAATGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC AGCAACATGT
  781 CGATGGACTT CCAGAACCAC CTGGGCAGCT GCCAAAAGTG TGATCCAAGC TGTCCCAATG
  841 GGAGCTGCTG GGGTGCAGGA GAGGAGAACT GCCAGAAACT GACCAAAATC ATCTGTGCCC
  901 AGCAGTGCTC CGGGCGCTGC CGTGGCAAGT CCCCCCAGTG ACTGCTGCCA CAACCAGTGT
  961 GCTGCAGCTG CACAGGCCCC CGGGAGAGCG ACTGCCTGGG TCTGCCGCAA TTTCCGAGAC
 1021 GAAGCCACGT GCAAGACACC TGCCCCCCCC ACTCATGCTT CTACAACCCC ACCACGTACA
1081 GATGGATGTG ATCCCCGAAG GTCAAATTAC AGCGTTTGGG GTGCTAC
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15495_A7K8b.seq check
>D04925A8_A7K8_2_pDONR_R_E06_15_ABI24.ab1
    1 GCGGACGTCA GGGTACGCTA TGACCATGTA ATACGACTCA CTATAGGGGA TATCAGCTGG
   61 ATGGCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC AAATTGATAA
  121 GCAATGCTTT CTTATAATGC CAACTTTGTA CAAGAAAGCT GGGTCGGCGC GCCCACCCTT
  181 TCATGCTCCA ATAAATTCAC TGCTTTGTGG CGCGACCCTT AGGTATTCTG CATTTTCAGC
  241 TGTGGAGCCC TTAAAGATGC CATTTGGCTT GGCTTCCTTG GGAAAGAAGT CCTGCTGGTA
  301 GTCAGGGTTG TCCAGGCTAA TTTGGTGGCT GCCTTTCTGG GCCCAGTGGG CAGGGCTGTC
  361 GAATGTGCTG TTGACACAGG TGGGCTGGAC AGTGTTGAGA TACTCGGGGT TGCCCACTGC
  421 AGTGCTGTGG GGGTCCTGGT AGTGTGGGTC TCTGCTGGGC GCGGGGTTCA GAGGCTGATT
  481 GTGATAGACA GGATTCTGCA CAGAGCCAGC GGGCCTTTTG GGAACGGACT GGTTTATGTA
  541 TTCAGGCACT GGGAGGAAGG TGTCGTCTAT GCTGTCCTCA GTCAAGGCGC CTGTGGGGTC
  601 TGAGCTGTAT CGCTGCAAGA AGCTGTCTTC CTTGATGGGA CAGCTTTGCA GCCCATTTCT
  661 ATCAATGCAA GCCACGGTGG AATTGTTGCT GGTTGCACTC AGAGAGCTCA GGAGGGGAGT
  721 CCGTGACGTG GAGGGGCTGC TGAAGAAGCC CTGCTGTGGG ATGAGGTACT CGTCGGCATC
  781 CACCACGTCG TCCATGTCTT CTTCATCCAT CAGGGCACGG TAGAAGTTGG AGTCTGTAGG
  841 ACTTGGGCAA ATGCATTCTT TCATCCCCCC TGAATGACAA GGTAGCGCTG GGGGGTCTCG
  901 GGCCATTTTG GAGAATTCGA TGATCAACTC ACGGAAACTT TGGGGCGACT ATCTGCGTCT
  961 ATCATCCAGC ACTTTGACCA TGATCATGTA GACATCGATG GGTACATATG GGTGGCTGAG
 1021 GGAGGGCGTT CTTCGTTTCT CAGGATGGAG GAGATCTCGC TGGGCAGGAA TTTCGTCATA
1081 TGACATGCAA TTCGAAGGTT CAATCCAACC TCCCAAAACA GT
//
Primer: EGFR-F5 (Pr0313)
Region: insert middle region (C797S, L858R)
Sequence file: RDB15495_A7K8c.seq check
>D04925A8_A7K8_2_EGFR-F5_F06_18_ABI24.ab1
    1 AACATAATCG TCATCGCCAC TGGGATGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
   61 CTGGGGATCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
  121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
  181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
  241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
  301 GTCGCTATCA AGGAATTAAG AGAAGCAACA TCTCCGAAAG CCAACAAGGA AATCCTCGAT
  361 GAAGCCTACG TGATGGCCAG CGTGGACAAC CCCCACGTGT GCCGCCTGCT GGGCATCTGC
  421 CTCACCTCCA CCGTGCAACT CATCACGCAG CTCATGCCCT TCGGCTCCCT CCTGGACTAT
  481 GTCCGGGAAC ACAAAGACAA TATTGGCTCC CAGTACCTGC TCAACTGGTG TGTGCAGATC
  541 GCAAAGGGCA TGAACTACTT GGAGGACCGT CGCTTGGTGC ACCGCGACCT GGCAGCCAGG
  601 AACGTACTGG TGAAAACACC GCAGCATGTC AAGATCACAG ATTTTGGGCG GGCCAAACTG
  661 CTGGGTGCGG AAGAGAAAGA ATACCATGCA GAAGGAGGCA AAGTGCCTAT CAAGTGGATG
  721 GCATTGGAAT CAATTTTACA CAGAATCTAT ACCCACCAGA GTGATGTCTG GAGCTACGGG
  781 GTGACCGTTT GGGAGTTGAT GACCTTTGGA TCCAAGCCAT ATGACGGAAT CCCTGCCAGC
  841 GAGATCTCCT CCATCCTGGG AGAAAGGAGA ACGCCTCCCT CAGCCACCCA TATGTACCAT
  901 CGATGTCTAC ATGATCATGG TCAAGTGCTG GATGATAGAC GCAGATAGTC GCCCAAAGTT
  961 TCCGTGAGTT TGATCATCGA AATTCTCCCA AAATGGCCCG AGACCCCCAG CGCTACCCTT
 1021 TGTTCATTCA AGGGGGAATG AAGAATGCCA TTTGGCTAGG TTCGTACAGA CCTCCGAACT
1081 CTACGCTGCC GTGAATTCAA TGCAGGAAGG ACATTG
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]